Why MacroGenics Is Moving Today

MacroGenics Inc MGNX shares are moving on Friday.

The company announced the FDA has granted Orphan Drug Designation to Margetuximab in the U.S. for gastric cancer.

Macrogenics is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates.

MacroGenics's stock was trading up 0.20% at $20.52 on Friday. The stock has a 52-week high of $29.50 and a 52-week low of $4.04.

Related Links:

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Moderna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate Annually